Anti-TNF antibodies, compositions, methods and uses

Patent metadata

Field	Value
Publication number	US-9321836-B2
Application number	US-201414068010-A
Country	US
Kind code	B2
Filing date	Feb 18, 2014
Priority date	Aug 7, 2000
Publication date	Apr 26, 2016
Grant date	Apr 26, 2016

Abstract

The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

First claim

What is claimed is:

1. A method for treating a TNF mediated condition, comprising
(a) contacting a sample from a subject with an isolated anti-TNF antibody having a variable region comprising SEQ ID NO:7 or 8;
(b) detecting whether TNF is present in said sample; and, if so,
(c) administering an effective amount of an isolated anti-TNF antibody having a variable region comprising SEQ ID NO:7 or 8.

2. A method according to claim 1 , wherein said effective amount is 0.001-50 mg/kilogram of said animal.

3. A method according to claim 1 , wherein said administrating is by a mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

4. A method according to claim 3 , further comprising administering, prior, concurrently or after said administering, a composition comprising an effective amount of a compound or protein selected from the group consisting of a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, or a cytokine antagonist.

Assignees

• Janssen Biotech Inc

Inventors

• Heavner George
• Knight David M
• Giles-Komar Jill
• Scallon Bernard
• Shealy David

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title